Recent Advances in Schizophrenia Management
March 21, 2019
March 21, 2020
Scroll to the Bottom of this Information to Begin this Course
Jointly provided by Postgraduate Institute for Medicine and PlatformQ Health Education, LLC.
This activity is supported by an educational grant from Indivior Inc.
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)™
All other health care professionals completing this course will be issued a statement of participation.
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and PlatformQ Health Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation StatementsLive Activity
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Date of Reliease/Expiration
Thursday, March 21, 2019 from 12:00pm – 1:00pm EDT.
The enduring material will be available from March 21, 2019 to March 21, 2020.
Upon completion of this activity, participants should be able to:
- Employ appropriate strategies when transitioning between oral antipsychotic agents and respective long‐acting antipsychotic injections in patients with schizophrenia
- Distinguish possible adverse metabolic abnormalities that may be associated with available antipsychotic agents
- Address clinical consequences of nonadherence to antipsychotic therapy with strategies to address nonadherence
- Assess the potential therapeutic benefits of newer and investigative agents in the treatment of schizophrenia
This activity is intended for psychiatrists, neurologists, nurse practitioners, physician assistants and primary care clinicians, and other health care providers who manage patients with schizophrenia.
Estimated Time to Complete
This activity consists of two sessions, which should take approximately 1 hours to complete.
Method of Participation
There are no fees to participate in this activity. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the posttest and activity evaluation. It is estimated that this module will take approximately 1 hours to complete. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the posttest.
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:.
Presenter: Seth J. Baum, MD, FACC, FACPM, FAHA, FNLA, FASPC
|Name of Faculty or Presenter||Reported Financial Relationship|
|Matcheri S. Keshavan, MD |
Stanley Cobb Professor and Vice-Chair for Public Psychiatry
Department of Psychiatry
Beth Israel Deaconess Medical Center and Massachusetts Mental Health Center
Harvard Medical School
|Rajiv Tandon, MD |
Executive Vice-Chair and Professor
Department of Psychiatry
University of Florida
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
|Name of Planner||Reported Financial Relationship|
|David Howard |
PlatformQ Health Education, LLC
The PIM planners and managers have nothing to disclose.
The following PlatformQ Health Education, LLC planner, Alissa Yost, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Disclosure of unapproved/off label use (if applicable):
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Please contact the Postgraduate Institute for Medicine at www.pimed.com.
For any technical issues or issues with your CME Certificate, please contact PsychiatryCareLive at 877-394-1306 or at Support@PsychiatryCareLive.
Information we collect is primarily used to communicate with program participants, award CME/CE credits, manage user accounts, recommend relevant programs and perform data analysis to inform educational outcomes.
In plain English, here is what we affirm:
- You can change your registration profile at any time from our “Profile” page
- To request any of these changes without logging in, please call us at 1 (877) 394-1306 or email us at support@PlatformQHealth.com
- You can end your association with PlatformQ Health at any time
- PlatformQ Health does not spam, nor we do we rent or sell our email list in whole or in part. Any program-related data sharing is for engagement verification and opt-in based further education
- EU citizens can request a complete record of their account and/or request to have their personal data expunged by contacting firstname.lastname@example.org with the subject line “Data Request”